Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

The mRNA treatment landscape is shaping up to be competitive, but the market is also nascent, with the covid pandemic marking the first commercial product from Moderna, the industry leader.

With only one commercial product – the COVID-19 vaccine – Moderna faces pressure to diversify its pipeline rapidly. As the company invests heavily in expanding its non-COVID mRNA vaccine ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20 ...

US vaccines developer Moderna today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine ...

The MRNA/MRK partnership's most advanced product ... Please note that these calculations are excluding potential profits from any of Moderna's commercial products. In this sense, the management ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands among Wednesday’s worst-performing stocks. The stock market declined on Wednesday, with all major indices ...

Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years. "This agreement presents an opportunity for Moderna to support and ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

MRNA’s first problem is the lack of near-term catalysts beyond infectious disease vaccines. The stock often swings on disease outbreaks, such as H5N1 avian flu last year, but this is unlikely to ...

Financial giants have made a conspicuous bullish move on Moderna. Our analysis of options history for Moderna (NASDAQ:MRNA) revealed 31 unusual trades. Delving into the details, we found 51% of ...